Valeant Pharmaceuticals International VRX
Valeant is mis-valued on a traditional earnings multiple; crediting its Pearson-led Platform Value — like Jarden or Danaher — unlocks $330+/share, ~48% upside from $223.
Thesis
Pershing Square argues that Valeant is systematically undervalued because the traditional multiple-of-earnings approach ignores 'Platform Value' — the future earnings power from Mike Pearson's demonstrated capital-allocation engine. By analogy to Martin Franklin's Jarden (~45x over 14 years), Platform Specialty (~175% in two years) and Nomad Holdings, the deck establishes that superior operator-acquirers deserve premium multiples. Valeant's decentralized operating model, ~5% cash tax rate and >20% unlevered IRR on $20bn+ of prior acquisitions — the Bausch & Lomb deal alone generating ~$13bn of value and lifting EBITDA margins from 21% to ~50% — qualify it as a high-value platform. Valuing the durable portfolio at 20x and patent-cliff exposure via DCF yields a blended 16.4x multiple and $330+ per share, 48% upside from $223, before any transformational acquisition or pipeline credit.
SCQA
Valeant is a specialty-pharma consolidator trading at $223 — roughly 14x management's implied $16 of 2016 EPS — built by CEO Mike Pearson through $20bn+ of disciplined acquisitions that have delivered 4,502% TSR since 2008.
Traditional multiple-of-earnings math values only the existing asset base and ignores Platform Value — the proven ability of operator-acquirers like Jarden, Danaher and Liberty to compound value through future disciplined acquisitions.
Re-rate Valeant via sum-of-the-parts: value durable products at 20x forward earnings (below the 23x healthcare and 25x non-healthcare comp averages), apply DCF to patent-cliff cash flows, and credit Pearson's continuing M&A engine at 4x leverage.
At $10bn of annual acquisitions at target returns, Valeant is worth $330+/share today (48% upside) and $518 by 2020 — before any transformational deal, pipeline revaluation or leverage above 4x EBITDA.
The three reasons
- 1
Jarden, Platform Specialty and Nomad prove operator-acquirer platforms generate 45x, 175% and 80% returns
- 2
Valeant has earned >20% unlevered IRR on $20bn+ of acquisitions; B&L alone went from $8.7bn to >$21bn
- 3
A blended 16.4x multiple on durable + cliff cash flows implies $330+/share today — ~48% upside from $223
Primary demands
- Re-rate Valeant using a sum-of-the-parts that credits Platform Value, not a single traditional earnings multiple
- Value the durable portfolio at 20x forward earnings and the patent-cliff portfolio via DCF
- Underwrite continuing disciplined acquisitions by Mike Pearson (up to $10bn/year at 4x leverage) as part of intrinsic value
KPIs cited
Pattern membership
Precedents cited
- Jarden under Martin Franklin (~45x return, 2001-2015)
- Platform Specialty Products / PAH (~175% in two years)
- Nomad Holdings / Iglo acquisition (~80% return)
- Danaher
- Liberty Media
- AB InBev
- TransDigm
- Valeant / Bausch & Lomb acquisition (130-160% value creation)
Slide gallery ·
Notes
Delivered by Ackman at the Sohn Investment Conference on May 4, 2015. Filename labels this the 'Second' Valeant presentation (first was the 2014 Valeant-Allergan hostile-bid deck co-authored with Valeant management). This is a defensive follow-up that generalizes Pershing's VRX long into a reusable 'Platform Value' framework. Structural signature: argument-by-analogy — spend the first ~13 pages proving platform value with Jarden, PAH and Nomad as case studies, then apply the framework to Valeant. Sum-of-parts split between 'durable' and 'patent-cliff' cash flows is the core analytical move, justifying 20x on durable vs 8x DCF on cliff. No stake disclosed in this deck. Tone is educational/analytical rather than adversarial — Mike Pearson is the hero-operator, not a target. Historically important as a canonical specimen of the compounder-acquirer thesis at its confident peak, and a cautionary tale given Valeant's collapse later in 2015-2016.